Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression

Synthetic Lethality Screen Identifies RPS6KA2 as Modifier of Epidermal Growth Factor Receptor Activity in Pancreatic Cancer

(2015) Nada Milosevic et al.   NEOPLASIA

Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K-Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma

(2014) M. H. Wong et al.   CLINICAL CANCER RESEARCH

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

ERCC1 and RRM1: Ready for Prime Time?

(2013) Benjamin Besse et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

(2013) Stefan Boeck et al.   JOURNAL OF GASTROENTEROLOGY

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer

(2013) Luc Friboulet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploring biomarkers in head and neck cancer

(2012) Corey J. Langer   CANCER

Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection

(2011) Shishir K. Maithel et al.   ANNALS OF SURGICAL ONCOLOGY

Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2011) Joshua A. Roth et al.   Clinical Lung Cancer

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

(2011) Jeeyun Lee et al.   LANCET ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

(2010) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY

A catalogue of reporting guidelines for health research

(2009) I. Simera et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

(2009) Elizabeth Poplin et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

(2009) R. Marone et al.   MOLECULAR CANCER RESEARCH

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

(2009) H Akita et al.   ONCOGENE

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

(2008) Volker Heinemann et al.   BMC CANCER

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation

(2008) D Balin-Gauthier et al.   BRITISH JOURNAL OF CANCER

Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation

(2008) George Fountzilas et al.   CANCER INVESTIGATION